Using FET-PET fused with MRI to better map and treat glioblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

At Copernicus Memorial Hospital, eligible adults with a single, contrast-enhancing glioblastoma will receive preoperative FET-PET scans and standard contrast-enhanced MRI that are fused to create a combined metabolic and anatomical map. The fused images will be used to inform the planned craniotomy and extent of tumor resection and to guide subsequent treatment planning. The protocol enrolls primary (nonrecurrent) tumors, patients aged 18–69 with KPS ≥70, and excludes multifocal disease or prior oncologic treatment. Study outcomes will focus on imaging-defined resection extent and early patterns of local recurrence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Single macroscopic tumor focus with the appearance of glioblastoma multiforme on MRI with contrast - contrast-enhancing lesion, completely or with central necrosis, with surrounding edema.
* No history of cancer in other organs. No suspicious lesions on X-ray of the chest and abdomen (CT with contrast).
* No clinical suspicion of brain abscess - no meningeal symptoms, signs of neuroinfection, fever, elevated inflammatory parameters.
* Primary tumor, without neurosurgical, radiotherapy or oncology intervention. Prior tumor biopsy is allowed.
* Tumor eligible for surgical treatment - craniotomy and tumor resection.
* Age ≥ 18 years but \< 70 years old.
* Quality of life assessment: KPS ≥ 70.
* Informed patient consent to the study and proposed treatment.
* No allergy to contrast agents used in PET and MRI.
* No medical contraindications to neurosurgery - craniotomy and resection.

Exclusion Criteria:

* Multifocal brain tumor.
* Recurrence of glioblastoma multiforme.
* Clinical or radiological suspicion of brain metastasis or brain abscess.
* Postoperative histopathological diagnosis other than WHO grade IV glioblastoma.
* Medical contraindications to any surgery under general anesthesia.
* Pregnancy, breastfeeding.
* Known allergy to gadolinium contrast or radiopharmaceutical tracing agent.

Where it's running

• Copernicus Memorial Hospital in Łódź, Poland
  Lodz, Łódź Voivodeship, Poland Recruiting

Study contacts

• Principal investigator: Kamil Krystkiewicz, PhD — Department of Neurosurgery and Neurooncology, Copernicus Memorial Hospital in Łódź, Poland
• Study coordinator: Kamil Krystkiewicz, PhD
• Email: kamil.krystkiewicz@gmail.com
• Phone: +48426895341

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• Adding ruxolitinib to standard radiation and temozolomide for newly diagnosed glioblastoma

  This trial will try whether adding the oral drug ruxolitinib to standard radiation and temozolomide helps adults newly diagnosed with glioblastoma.

  Recruiting at 2 sites Phase 2 Baptist Health South Florida · Miami, Florida and 1 other locations · NCT06991101

• Radiation plus tarlatamab for DLL3-expressing tumors

  This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.

  Recruiting at 3 sites Phase 1/2 University of Arizona · Gilbert, Arizona and 2 other locations · NCT06814496

• Using low-intensity magnetic therapy for newly diagnosed glioblastoma patients

  This study is testing whether a low-intensity magnetic therapy device can safely help people who have just been diagnosed with glioblastoma.

  Recruiting at 6 sites BioTex, Inc. · Stuttgart, Baden-Wurttemberg and 5 other locations · NCT06533163

• Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma

  This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.

  Recruiting at 2 sites Phase 3 NaviFUS Corporation · Taipei and 1 other locations · NCT06496971

• Neoadjuvant radiochemotherapy for glioblastoma treatment

  This study is testing a new combination of radiation and chemotherapy before surgery to see if it helps people with glioblastoma feel better and live longer compared to standard treatment.

  Recruiting Phase 1 Hospital San Carlos, Madrid · Madrid · NCT06418113

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.